Key points are not available for this paper at this time.
Rosacea, a common and chronic skin disorder, presents with various cutaneous manifestations. The phenotype of rosacea determines the approach to treatment. Refractory rosacea with persistent erythema invariably necessitates pharmacologic agents. Herein, we report a case series on three female patients with persistent erythema of rosacea treated by abrocitinib, a JAK-1 inhibitor.
Teng et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: